ABSTRACT

Introduction: Ixekizumab (IXE), a high affinity humanized monoclonal antibody that selectively targets interleukin-17A, is approved in the United States (US) and the European Union (EU) for pediatric patients with moderate to severe plaque psoriasis. This review summarizes ixekizumab use in the phase 3, randomized, double-blind, placebo-controlled study in pediatric patients with moderate to severe plaque psoriasis and provides some clinical pearls we have learned after using the drug in the pediatric population for the past 3 years.

Areas covered: Review of IXORA-PEDS trial data, general literature review pertaining to the systemic treatment of pediatric psoriasis as well as our clinical experience with IXE

Expert opinion: IXE is the only IL17 antagonist for pediatric psoriasis and is a welcome addition to our armamentarium.

摘要

简介： Ixekizumab (IXE) 是一种选择性靶向 IL-17A 的高亲和力人源化单克隆抗体，已在美国 (US) 和欧盟 (EU) 获批用于中度至重度斑块型银屑病儿科患者。这篇综述总结了 ixekizumab 在中度至重度斑块型银屑病儿科患者的 3 期、随机、双盲、安慰剂对照研究中的使用，并提供了过去 3 年在儿科人群中使用该药物后我们学到的一些临床珍珠.

涵盖的领域：IXORA-PEDS 试验数据的回顾、与小儿银屑病系统治疗有关的一般文献回顾以及我们在 IXE 方面的临床经验

专家意见：IXE 是唯一一种用于治疗小儿银屑病的 IL17 拮抗剂，是我们医疗器械中受欢迎的补充。